and it's not just -- it's not just amgen. we are talking about very similar base formations in all of the major big pharmaceutical names as well. >> well, that's interesting. let me bring in josh. josh, you would herd people towards pfizer as opposed to amgen. >> yeah. i guess pfizer is probably moving with the rest of the group, x you probably saw the same breakout we did. we pulled the trigger on a long. where do you stand on pfizer versus something a little bit more exciting like a biotech? or do you think it's just a general trend for most of them to work their way higher? >> i think it's a general trend. you know, when we do -- when we go back and look at attribution and the work of what drives stocks, such a big proportion of the attribution of a stock's moves is the group and the sector to which it's related. and so, you know, it's as much as anything to me a sector in group call as it is an individual stock call. look, pfizer looks just the same to us as bristol, as amgen and the rest of them. they are very good long-

. >> let's move and talk about shares of amgen. j.b., it's a stock you've been bullish on. >> we like the action of biotechs. pull the trigger. >> stay long on the market. use the xbi. you get it on all of them. >> new 52-week-high as we speak. like it. >> gee, that's a lot of josh brown for you. >> makes me sound like a broken record. scott, look at the chart on amgen. this thing has been coiled. it's broken out of 80, 81. there's no resistance ahead of it. they beat earning consensus by $440 million. tell me any market that's done that. the bottom line on biotech, amgen is the biggest. gilliland as well. there are few biotechs in the market. the good ones don't become public. they get bought out. the remaining, i want to own all of them. i reiterate, we're in an xbi. >> let's talk sprint, raised to buy from neutral ubs. grasso? >> that four-year deal to sell the iphone for $15.5 billion was so questioned among the investment community. it turns out to be the one thing that saved the stock with average data plans and the money spe

amgen, coinstar, or starbucks. the greatest empires. then, some said, we lost our edge. well today, there's a new new york state. one that's working to attract businesses and create jobs. a place where innovation meets determination... and businesses lead the world. the new new york works for business. find out how it can work for yours at thenewny.com. well another great thing about all this walking i've been doing is that it's given me time to reflect on some of life's biggest questions. like, if you could save hundreds on car insurance by making one simple call, why wouldn't you make that call? see, the only thing i can think of is that you can't get any... bars. ah, that's better. it's a beautiful view. i wonder if i can see mt. rushmore from here. geico. fifteen minutes could save you fifteen percent or more on car insurance. the heart of every innovation. wow. that feels really good! and now, sleep number introduces our new memory foam series-the only memory foam beds with exclusive dual-air technology that adjusts on each side. memory foam just found its better ha

that's what gilead, amgen and sellya was giving you.ek high for am jen products that can work in cases were others failed. doesn't hurt the core business is on fire. including the older drugs which were responsible for delicious upside earning surprise. many people believe the best compound for he c. it could be worth billions and billions. that could be as early as 2014. it has made many people believe that the best compound is gilead's. they were much better than expected. people wrote this company off, but confident the franchise remains intact and thriving and number of initiatives celgene has could lead to earnings outside. given its stellar profits, much better than expected, it is an inexpensive stock with many years of growth ahead of it. i said that even after the stock went over $3. you know i like dividends, don't like expensive stocks. if anything, one particular drug prospect goes awry, but the three old biotech companies proved themselves time and time again, while they aren't for the feint of heart, you can get long-term

merck and amgen were names that were high. >> where did we see option, bullish options activity. the utilities. then where do you see bearish things? cyclical option trades were bearish and safety trades were bullish napts not the kind of sentiment you want to see from the options markets to suggest all is well. >> because of this whole beat on earnings and miss on revenue, it's like it's 2008 or 2009 again. if we're still muddling through that's not a good thing. one thing interesting today was the trade in ama stone. horrible number. people are buying the whole amazon, investing in the business story. i bought that a few quarters ago. the stock really did well, amazingly well. i do think it's interesting the vix is not lower than it is now. people are inned in getting a little protection. we talk about the ecb. everything is great now but in a couple of weeks things in europe can be horrible. >> if you shoot a dead body it will still move. >> a terrible metaphor. it's been a rally of the defensive sectors. you mentioned utilities. telecom hitting highest levels since 2008. ther

merck, amgen. >> and take a look at the options activity where did we see bullish options activity. x lu. utilities etf. and bearish things, eem. cyclical options trades were bearish and safety trades were bullish. not the kind of sentiment you want to see from options markets to suggest all is well. >> well, because of the whole beat on earnings, miss on revenue, like 2008, 2009 again. if we're muddling through, not a good thing. one thing really interesting, the trade in amazon, horrible number. terrible number. people are buying the whole amazon, investing in the business story. i bought that a few quarters ago. now a little old. but the stock really did well, amazingly well, i do think it's interesting that the vix is not lower than it is right now. people still interested in getting a little protection. we talk about the ecb. everything is great now, but in a couple weeks, everything in europe could be horrible. >> if you apply shock to a dead body, it will still move. >> that's a terrible metto for, mike. it has been a rally of defensive sectors. utilities, tell cons, highest si

also getting a strong earnings report from amgen, up better than 4%, and let's talk tires for a second. good year and cooper tire gaining ground after michellin reported a loss. and we have two losers in the biotech space. we have a buy on the rumor sell on the situation here. amarin's fish oil drug getting the backing of the fda, and this company also getting an approval. amarin is up over 0%, and horizon has doubled over the last four. we're in the final stretch for the day and the week. this market is holding on to a 212 point gain, near the highs of the day right now at 13,100. don't miss a moment of what we have ahead. >> coming up, facebook hitting all time lows. it may not be over yet. why one well known tech investor says there's more reason to be concerned. is it time to update the status of facebook's leadership with a more business savvy ceo. >> maria, i will not accept this form of discussion -- the rule, you can define -- i'm sorry, please let me finish. and what has congressman barney frank so worked up. the answer, later on the "closing bell"i st want to give her everyth

amgen shares up .6% and not seen since february of 2006 and moving on to vivus.y have a weight loss drug waiting for approval from the fda. finding out tomorrow if it gets approv approval. the drug get approval and saw a stock shoot up higher. the market is optimistic. look at gilead. mandy and brian, back to you. >> thank you so much for that. we were talking about the hunt for yield at any cost and then bob was saying a lot of people who instant safety at any cost and in other words going in to bonds and you were pointing out here, property group. >> 2.5%. also one place is reits to put the money. >> okay. we have lots of economic indicators this week including a read on housing and jobs so what should we be looking for in the markets ahead of the numbers? joining us is jim godfrey and david fleischer. gema, leets get to you. i think 20% of the s&p coming out with the numbers. i was reading your notes though saying that market elation at the moment has been misguided and i was like, market elation. where's the elation? we are down for the seventh straight monda

it is not dominated by amgen and celgene. >> how about nat gas?now if it is a surprise, some with what of under the radar move given everything else going on and so much of the focus in the energy space and take a look at nat gas pushing closer to $3 again. >> it is interesting. the first three months of the year nat gas fell 21%. i think you had short covering and buying going on and the buy we play it it through devan energy and i also like southwest energy and eog resources. they're all still very cheap. >> fears of acorn shortage sending futures higher. up together again as sweltering temperatures and droughts in the midwest are threatening crops and the commodities king joins us with his trade here. welcome to the show. good to have you. hope you had a good fourth, maybe ate corn on the cob or something. what's happening with corn? how are you trading it? >> you have to be long. it is amazing what's happening to the size of this crop. three weeks ago you would think we would have a record crop, maybe 14.7 billion bushels and the crop was in t

and i have to tell you this, this and amgen doing remarkable work. cancer, a new kind of staten for people who didn't take the old ones. these biotech companies are back. turns out that everyone's very excited about them. and celgene the other day reported better-than-expected -- >> enormous market cap biotechs. these are the big guys. . we have a lot more stocks to watch after that opening bell. it's just three minutes away. stay with us. [ male announcer ] let's level the playing field. take the privileged investing tools of wall street and make them simple, intuitive, and available to all. distill all that data. make information instinctual, visual. introducing trade architect, td ameritrade's empowering web-based trading platform. take control of your portfolio today. trade commission-free for 60 days, and we'll throw in up to $600 when you open an account. >>> and the last trading session of the week begins. here at the big board, cohen and steers. over at the nasdaq, onboard. the big focus here, facebook hitting a fresh low in the session. $23.

gilead and jell cnn were strong and amgen. and then starbucks blew up.t was a terrible quarter. >> but the leaders have been the companies that have been largely domestic, though not entirely. kimberly clark sells plenty of diapers all over the world and have a very significant dividend. we hit 1.55 on the ten-year. the yield is soaring. >> you can't own the ten-year because that's where -- everyone owns the ten-year. how many years have we -- have people said that's the most dangerous piece of paper in the world? i wish that the stocks i follow were as dangerous as the ten-year. >> right. >> well, europe, of course, still will have an impact over here. european stocks extending last week's rallies. spanish bonds falling today and falling fast over the last week, as eu leaders send more signals they are prepared to tack it will debt crisis. jean-claude junker says leaders will decide in the coming day what is measures to take after mario draghi said the central bank will do whatever it takes to save the euro. tim geithner set to meet today with draghi an

amgen getting a boost, earnings beating the street on strong demand for many of its drug. raised its full year earnings and revenue forecast. >> steve, thank you very much. let's take a look at the markets this morning and after that big rally yesterday we saw it continue throughout the day. let's look at the future. you'll see right now at least the futures are a little mixed. the dow futures are up by 12 points. nasdaq is down by over one point. everybody is waiting to see what happens with this huge gdp number. this is going to set the table for what we can expect to hear from the fed next week. steve, i don't want to go too far off tangent but this idea that the fed could step in if the number is really weak would they do that before the jobs numbers? >> i think if this number is very weak and it's not due to be sort of one off reasons they could move next week. what was not clear to me from the rhetoric and the articles that have been out and when i listen tocy think the fed is ready to do something. it's not clear they agreed on what they should do and can do. >> tak